Axela Biosensors and Abnova signed a collaborative agreement to co-develop reagents and biomarker panels for use on Axela’s dotLab System. The dotLab System provides for the analysis, validation, and commercialization of protein biomarkers.
“These products will target a significant bottleneck in biomarker validation,” says Wilber Huang, president of Abnova. “Our ability to generate highly specific antibodies on an industrial scale combined with the levels of sensitivity and quantitation of the dotLab System will improve and accelerate the ability of pharmaceutical and translational medicine researchers to validate medically important biomarkers.”
Abnova will optimize a series of Mabs for the quantitation of specific serum protein biomarkers for use with Axela’s dotLab Sensors. Researchers will be able to combine these Mabs with their own reagents to create custom panels for multiplexed biomarker detection.